Brief: Karolinska Development's Portfolio Company Reports Promising Preclinical Results For Candidate Drug

Kdventures AB

28/09/2023 12:45

Sept 28 (Reuters) - Karolinska Development AB  KDEV.ST :
    * PORTFOLIO COMPANY PHARMNOVO REPORTS PROMISING PRECLINICAL
RESULTS ON ABUSE POTENTIAL AND WITHDRAWAL SYMPTOM RELIEF FOR ITS
CANDIDATE DRUG PN6047
    * RESULTS REAFFIRM EXISTING SAFETY PROFILE DATA OF PN6047,
WHICH
IS PLANNED TO ENTER CLINICAL PHASE 2 TRIALS IN 2024
    * KAROLINSKA DEVELOPMENT'S OWNERSHIP IN PHARMNOVO IS 13.1%
    * NEW PRECLINICAL RESULTS SHOW THAT DRUG CANDIDATE DOES NOT
INDUCE
DRUG ABUSE BEHAVIOR IN NON-CLINICAL TEST MODELS

Source text for Eikon:  ID:nGNEx6sfV 
Further company coverage:  KDEV.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))